natgillin/translations-raw huggingface dataset:
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Tecfidera’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas seetõttu, et Tecfidera kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that the benefits of Oncaspar are greater than the risks and recommended that it be approved for use in the EU.
Inimravimite komitee järeldas seega, et Oncaspari kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that the benefits of Spectrila are greater than the risks and recommended that it be approved for use in the EU.
Inimravimite komitee järeldas seega, et Spectrila kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Unituxin’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee järeldas seetõttu, et Unituxini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Alprolix’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Alprolixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Cabometyx’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Cabometyxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Epclusa’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Epclusa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Episalvan’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Episalvani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Idelvion’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Idelvioni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Kisplyx’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Kisplyxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Lartruvo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Lartruvo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Praxbind’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Praxbindi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Wakix’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Wakixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore decided that Zepatier’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Zepatieri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Advocate’s benefits are greater than its risks and recommended that Advocate be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Advocate kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Aivlosin’s benefits are greater that its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Aivlosini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Bravecto’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Bravecto kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that BTVPUR’s benefits are greater that its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et BVTPURi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Canigen L4’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et vaktsiini Canigen L4 kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Clomicalm’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Clomicalmi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Draxxin’s benefits are greater than its risks and recommended that it be approved in the EU.
Veterinaarravimite komitee järeldas, et Draxxini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Eravac’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Eravaci kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Evalon’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Evaloni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Imrestor’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Imrestori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Innovax- ILT’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Innovax-ILT kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Letifend’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Letifendi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Metacam’s benefits are greater than its risks and they recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Metacami kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that MS-H Vaccine’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et MS-H-vaktsiini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Porcilis PCV ID’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Porcilis PCV ID kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Poulvac E. coli’s benefits are greated that its risks and recommended that it be approved in the EU.
Inimravimite komitee järeldas, et Poulvac E. coli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Profender’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Profenderi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Reconcile’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Reconcile kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that SevoFlo’s benefits are greater that its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et SevoFlo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Simparica’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Simparica kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Suvaxyn Circo+MH RTU’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Suvaxyn Circo+MH RTU kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that UpCard’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et UpCardi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Vectormune ND’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Vectormune ND kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Velactis’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Velactise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that ZACTRAN’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et ZACTRANi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Zulvac SBV’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Zulvac SBV kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Zycortal’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Zycortali kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in accordance with EU requirements, Inflacam has been shown to have comparable quality and to be bioequivalent to Metacam.
Veterinaarravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Inflacam võrdväärne kvaliteet ja bioekvivalentsus ravimiga Metacam.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in accordance with EU requirements, Novaquin has been shown to have comparable quality and to be bioequivalent to Metacam.
Veterinaarravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Novaquin võrdväärne kvaliteet ja bioekvivalentsus ravimiga Metacam.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in accordance with EU requirements, Sedadex has been shown to have comparable quality to Dexdomitor.
Veterinaarravimite komitee järeldas, et Euroopa Liidu nõuete kohaselt on tõendatud ravimi Sedadex sarnane toime ravimiga Dexdomitor.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in accordance with EU requirements, Sevohale has been shown to be comparable to SevoFlo.
Veterinaarravimite komitee järeldas, et Euroopa Liidu nõuete kohaselt on tõendatud ravimi Sevohale sarnane toime ravimiga SevoFlo.
The Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) decided that Fortekor Plus’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Veterinaarravimite komitee järeldas, et Fortekor Plusi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agenerase oral solution contains 15 mg/ml of amprenavir.
Lahus sisaldab 15 mg/ml amprenaviiri.
The agreement rate for the image obtained with Rapiscan or adenosine relative to the initial adenosine image was calculated by determining how frequently the patients assigned to each initial adenosine category (0-1, 2-4, 5-17 reversible segments) were placed in the same category with the randomised scan.
Rapiscani või adenosiini kasutamisel saadud skaneeringute leppemäära arvutamiseks võrreldes esimese adenosiiniskaneeringuga määrati kindlaks see, kui sageli määrati igasse esimesse adenosiinikategooriasse (0-1, 2-4, 5-17 pöörduvat segmenti) kuulunud patsiendid samasse kategooriasse ka randomiseeritud skaneeringul.
The agreement rates for Rapiscan and adenosine were calculated as the average of the agreement rates across the three categories determined by the initial scan.
Rapiscani ja adenosiini leppemäärad arvutati keskmiste leppemääradena kõigi kolme kategooria kohta, mis määratleti esimesel skaneerimisel.
The aim is to implement similar wording across all products concerned to optimize risk minimisation and ensure consistency in information provided to patients.
Eesmärk on kasutada sarnast sõnastust kõikide preparaatide puhul, mida riski minimeerimise optimeerimine puudutab ja tagada patsientidele mõeldud teabe ühtivus.
The aim of Rienso therapy is to replenish the body’s iron stores.
Rienso-ravi eesmärk on täiendada keha rauavarusid.
The aim of the study was to assess efficacy, safety, and tolerability of Ilaris (150 mg or 2 mg/kg every 8 weeks) in patients with CAPS.
Uuringu eesmärk oli hinnata Ilaris’e (150 mg või 2 mg/kg iga 8 nädala järel) efektiivsust, ohutust ja talutavust CAPS patsientidel.
The aim of the treatment initiation form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse reactions associated with the use of thalidomide.
Ravi alustamise teatise vormi eesmärgiks on kaitsta patsienti ja võimalikku loodet tagades, et patsienti on põhjalikult teavitatud talidomiidi kasutamisest tingitud teratogeensuse ohust ja muudest kõrvalnähtudest ja et ta saab nendest aru.
The aim of the treatment is to keep blood levels of homocysteine below 15 micromoles or as low as possible.
Ravi eesmärk on hoida homotsüsteiini tase vereplasmas alla 15 mikromooli või võimalikult madal.
The aim of this part of the study was to assess whether treatment with Ilaris allowed a reduction in the use of steroids in at least a quarter of patients.
Selle uuringuosa eesmärk oli hinnata, kas Ilaris vähendas patsientidest vähemalt veerandil steroiditarvet.
The aims of this Registry are to increase the understanding of Gaucher disease and to check how well enzyme replacement therapy, like Cerezyme, works.
Selle registri eesmärgiks on Gaucher’ tõbe paremini tundma õppida ja kontrollida, kui tõhus on ensüümasendusravi Cerezyme’iga.
The albumin-bound fraction and the unbound fraction are collectively termed ‘bioavailable’ testosterone.
Albumiiniga seondunud fraktsiooni ja seondumata fraktsiooni nimetatakse üheskoos “biosaadavaks” testosterooniks.
The alendronate component in the ADROVANCE (70 mg/2,800 IU) combination tablet and the ADROVANCE (70 mg/5,600 IU) combination tablet is bioequivalent to the alendronate 70 mg tablet.
Alendronaat ADROVANCE’i (70 mg/2800 RÜ) kombinatsioontabletis ja ADROVANCE’i (70 mg/5600 RÜ) kombinatsioontabletis on bioekvivalentne alendronaadi 70 mg tabletile.
The alendronate component in the FOSAVANCE (70 mg/2,800 IU) combination tablet is bioequivalent to the alendronate 70 mg tablet.
Alendronaat FOSAVANCE’i (70 mg/2800 RÜ) kombinatsioontabletis on bioekvivalentne alendronaadi 70 mg tabletile.
The alendronate component in the FOSAVANCE (70 mg/5,600 IU) combination tablet is bioequivalent to the alendronate 70 mg tablet.
Alendronaat FOSAVANCE’i (70 mg/5600 RÜ) kombinatsioontabletis on bioekvivalentne alendronaadi 70 mg tabletile.
The alendronate component in the VANTAVO (70 mg/2800 IU) combination tablet is bioequivalent to the alendronate 70 mg tablet.
Alendronaat VANTAVO (70 mg/2800 RÜ) kombinatsioontabletis on bioekvivalentne alendronaadi 70 mg tabletile.
The alendronate component in the VANTAVO (70 mg/5600 IU) combination tablet is bioequivalent to the alendronate 70 mg tablet.
Alendronaat VANTAVO (70 mg/5600 RÜ) kombinatsioontabletis on bioekvivalentne alendronaadi 70 mg tabletile.
The alli website (please refer to your country specific website included in the list of local representatives above) provides you with a range of interactive tools, lower-fat recipes, physical activity tips and other useful information to help you lead a healthy life and to support you in meeting your weight loss goals.
alli koduleheküljelt leiate sobivaid, vähese rasvasisaldusega retsepte, nõuandeid füüsilise koormuse suurendamiseks ja muud kasulikku teavet, mis aitavad teil elada tervislikku elu ning toetavad teid kaalulangetamise eesmärkide saavutamisel.
The alli weight loss programme combines the capsules with an eating plan and a wide range of resources to help you understand how to eat a reduced calorie, lower-fat diet and guidelines for becoming more active.
alli kaalulangetamise programm aitab teil aru saada, kuidas süüa madala kalorsusega ja vähese rasvasisaldusega toitu ja annab juhiseid füüsilise aktiivsuse suurendamiseks.
The alopecia and irritation are normally self-resolving, but symptomatic therapy may be applicable in some circumstances.
Alopeetsia ja ärritus mööduvad normaalselt iseenesest, kuid mõningatel juhtudel võib kasutada sümptomaatilist ravi.
The alpha particle range from radium-223 is less than 100 micrometers (less than 10 cell diameters) which minimises damage to the surrounding normal tissue.
Raadium 223 alfaosakeste ulatus on väiksem kui 100 mikromeetrit (so vähem kui 10 raku diameetrit), mis vähendab ümbritseva normaalse koe kahjustamist.
The alterations were not considered clinically relevant, since pharmacodynamic effects based on bone turnover markers were consistent across a wide range of body weight.
Kõikumisi ei peetud kliiniliselt olulisteks, sest luukoe ainevahetuse markerite alusel olid farmakodünaamilised toimed ühetaolised kehakaalu laias vahemikus.
The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains A/equine-2/South Africa/4/03 and A/equine-2/Newmarket-2/93, is recommended to maintain immunity levels for the influenza component (see scheme).
Tagamaks gripikomponendi vastast immuunsustaset on alternatiivseks kasutamiseks 12- kuulise intervalliga sobiv hobuste gripivastane vaktsiin, mis sisaldab tüvesid A/equine-2/South Africa/4/03 ja A/equine 2/Newmarket-2/93 (vt. skeemi).
The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains A/equine-2/South Africa/4/03and A/equine-2/Newmarket-2/93, is recommended to maintain immunity levels for the influenza component (see scheme).
Tagamaks gripikomponendi vastast immuunsustaset on alternatiivseks kasutamiseks 12-kuulise intervalliga sobiv hobuste gripivastane vaktsiin, mis sisaldab tüvesid A/equine-2/South Africa/4/03 ja A/equine 2/Newmarket-2/93 (vt. skeemi).
The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains, A/equine-2/South Africa/4/03 and A/equine-2/Newmarket-2/93, is recommended to maintain immunity levels for the influenza component (see scheme).
Tagamaks gripikomponendi vastast immuunsustaset on alternatiivseks kasutamiseks 12-kuulise intervalliga sobiv hobuste gripivastane vaktsiin, mis sisaldab tüvesid A/equine-2/South Africa/4/03 ja A/equine 2/Newmarket-2/93 (vt. skeemi).
The amidase FAAH was able to catalyse the formation of NW-1153 at low rates only.
Amidaas FAAH suutis NW-1153-e moodustumist katalüüsida vaid väikestel kiirustel.
The amino acid sequence of the recombinant form, as well as the nucleotide sequence which encoded it, are identical to the natural form of -galactosidase.
Rekombinantse vormi aminohappeline järjestus, samuti ka seda kodeerinud nukleotiidide järjestus, on identsed -galaktosidaasi loodusliku vormiga.